Novo counters compounders with direct access channel for Wegovy, price cut for self-paying patients
Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies that have been producing cheaper versions of their popular obesity prod | The move follows a similar price cut by Eli Lilly as both GLP-1 drugmakers attempt to fend off cheaper compounded versions of their popular obesity meds.
Zacks Investment Research on MSN1d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
13hon MSN
Novo Nordisk’s GLP-1 drug Semaglutide, sold under brand names Ozempic and Wegovy, has been hailed as a miracle drug for ...
Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders over whether its blockbuster drugs Wegovy ...
Medical treatments, including jabs used for weight loss, are monitored in part using the Medicines and Healthcare products ...
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
The i Paper on MSN8d
Weight-loss jabs like Wegovy linked to dozens of UK deaths - here are the factsSome health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...
Novo Nordisk 's ( NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback